Analyst Reco. Johnson & Johnson London S.E.

Equities

0R34

US4781601046

Market Closed - London S.E. Other stock markets 09:05:27 21/06/2024 pm IST			After market 01:35:21 am
148.3 ^USD	+1.71%		148.8	+0.36%

07:49pm	Sector Update: Health Care Stocks Edge Up in Afternoon Trading	MT
02:39pm	Johnson & Johnson: filing in Crohn's disease	CF

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	06/06	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	01/05	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	25/04	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	22/04	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	18/04	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	18/04	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	18/04	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	17/04	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	17/04	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	17/04	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	17/04	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	17/04	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	09/04	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	05/04	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	05/04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	24/01	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	24/01	MT
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	09/01	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	03/01	MT
ANALYST RECOMMENDATIONS : Adobe, Airbnb, Netflix, Nike, Etsy...	14/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST